Gapping down
In reaction to disappointing earnings/guidance:
- NCS -13.4%, ABM -4.8%, LEG -3.5%, DSGX -1.6%, GIS -1.3%
Other news:
- ALNY -12% (provides pipeline update on Fitusiran and Givosiran; Fitusiran dosing suspended due to thrombotic event)
- AM -6.9% (prices secondary offering 10 mln common units held by Antero Resources Corp (AR) at $31.45 per unit)
- KEM -6% (confirms public secondary offering of 8,416,814 shares of its common stock upon exercise of warrant held by the selling securityholder)
- BLDR -3.4% (prices 13,482,177 shares of its common stock at $16.30/share)
- NEP -1.4% (announces offering of $300 million in aggregate principal amount of convertible senior notes due 2020)
- CELG -0.8% (FDA has placed a partial clinical hold on five trials and a full clinical hold on one trial in the Celgene FUSION program)
- NWE -0.7% (establishes 'at-the-market' equity offering program to sell up to of $100 mln of its common stock)
Analyst comments:
- RACE -4.1% (downgraded to Underweight from Overweight at Morgan Stanley)
- TRHC -3.6% (downgraded to Market Perform from Outperform at Wells Fargo)
- SEE -1.5% (downgraded to Neutral from Buy at Citigroup)
- CMC -1.1% (initiated with a Underperform at Macquarie)
- KAR -0.7% (downgraded to Equal-Weight from Overweight at Stephens)
